Search results
Author(s):
Christina Magnussen
Added:
1 year ago
ACC 2025 - Individual-level data collected across 126 worldwide cohorts show controlling modifiable cardiovascular risk factors can potentially benefit life-years for freedom from CVD and death from any cause.Prof Christina Magnussen (University Heart and Vascular Centre Hamburg, Hamberg, DE) joins us onsite at ACC to discuss modifiable cardiovascular risk factors collected by the Global…
View more
Author(s):
Meriem Perona
,
Amanda Cooklin
,
Christopher Thorpe
,
et al
Added:
1 year ago
Added:
1 month ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc secondary analysis of the SOUL trial has found that once-daily oral semaglutide is associated with early and sustained improvements in multiple cardiovascular (CV) risk factors in high-risk patients with type 2 diabetes (T2D).¹ These findings help to explain the mechanisms behind the primary trial results, which showed a 14% reduction in major adverse…
View more
Author(s):
Cristina Helguera Amezua
,
Laura Pérez Bacigalupe
,
Diego Manuel de la Eranueva
,
et al
Added:
1 month ago
Preterm Birth and Maternal Cardiovascular Risk
Author(s):
Jorge Segovia-Reyes
,
Andrea Iboleon-Jimenez
,
María Jiménez-Salva
,
et al
Added:
1 month ago
Review Article
Frailty and Cardiovascular Risk
Author(s):
Nicholas R Evans
,
Shiv Bhakta
,
Claudia Zeicu
,
et al
Added:
1 month ago
Review Article
Author(s):
Kausik Ray
,
Upendra Kaul
,
Srinivasa Rao
,
et al
Added:
6 months ago
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Author(s):
Joshua Stolker
,
Philippe Gabriel Steg
,
Roberta Rossini
,
et al
Added:
1 year ago
Expert Opinion
Factor XIa Inhibitors’ Future Position in AF
Author(s):
Maki Komiyama
,
Moritake Iguchi
,
Hiromichi Wada
,
et al
Added:
1 year ago
Expert Opinion
Factor XI Inhibition and AF
Author(s):
Bianca Rocca
,
Hugo ten Cate
Added:
1 year ago
Expert Opinion